Emtricitabine/rilpivirine/tenofovir
From Wikipedia, the free encyclopedia
| Combination of | |
|---|---|
| Emtricitabine | Nucleoside analog reverse-transcriptase inhibitor |
| Rilpivirine | Non-nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil fumarate | Nucleoside analog reverse-transcriptase inhibitor |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ℞-only (US) ℞ Prescription only |
| Routes | Oral |
| Identifiers | |
| ATC code | J05AR08 |
 (what is this?) (verify) |
|
Emtricitabine/rilpivirine/tenofovir (trade name Complera, Eviplera) is a fixed dose combination of antiretroviral drugs for the treatment of HIV.[1] The drug was co-developed by Gilead Sciences and Johnson & Johnson's Tibotec division and was approved by the Food and Drug Administration in August 2011, and by the European Medicines Agency in November 2011 (Eviplera),[2] for patients who have not previously been treated for HIV.[3] It is available as a once-a-day single tablet.
References [edit]
- ^ "Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination". Food and Drug Administration. August 10, 2011.
- ^ "Eviplera; summary of the European public assessment report". European Medicines Agency. November 2011.
- ^ "FDA approves Gilead-J&J HIV pill Complera". Business Week. August 10, 2011.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
